They described the case report of an ALK-RCC patient who relapsed after complete resection of the tumor and, therefore, received first-line treatment with entrectinib, a selective TKI towards neurotrophic tyrosine receptor kinase (NTRK), ROS1, and ALK fusion. The gene discussed is ALK; the disease is renal cell adenocarcinoma.